Repeated transfusions of genetically modified cells are required in $SCID$ patients and in enzyme replacement therapy because
Repeated transfusions of genetically modified cells are required in $SCID$ patients and in enzyme replacement therapy because
- A
Transfused cells have a limited life span
- B
Introduced gene has been mutated
- C
The enzyme required is degraded after $20\; days$ of transfusion
- D
Both $(a)$ and $(c)$
Similar Questions
Taking examples under each category, discuss upstream and downstream processing.
Taking examples under each category, discuss upstream and downstream processing.
Hybridomas are result of the fusion of
Hybridomas are result of the fusion of
The critical research areas of biotechnology are
$I$. providing best catalyst as improved organism, usually a microbes or pure enzyme
$II$. creating optimal conditions by engineering for a catalyst to act
$III$. down stream processing technologies
$IV$. Multiple Ovulation Transfer Technology $(MOET)$
Which of the statements given above the correct?
The critical research areas of biotechnology are
$I$. providing best catalyst as improved organism, usually a microbes or pure enzyme
$II$. creating optimal conditions by engineering for a catalyst to act
$III$. down stream processing technologies
$IV$. Multiple Ovulation Transfer Technology $(MOET)$
Which of the statements given above the correct?
The grafting principle depends upon the
Who among the following scientists is associated with the discoveries in genetic engineering
Who among the following scientists is associated with the discoveries in genetic engineering